Department of Surgery and Miami Transplant Institute, University of Miami, Miller School of Medicine, Miami, Florida, USA; Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, Florida, USA; Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Kidney Int. 2019 Mar;95(3):498-500. doi: 10.1016/j.kint.2018.11.032.
Focal segmental glomerulosclerosis is a glomerular disorder with a high rate of recurrence. Although kidney biopsies remain the gold standard to diagnose recurrent focal segmental glomerulosclerosis, non-invasive prognostic assays could facilitate preventive treatments and offer insight into disease pathogenicity and heterogeneity. Srivastava et al. describe a simple, cell-based assay to predict recurrence of focal segmental glomerulosclerosis. Although the study needs to be optimized and validated, its novelty is that it does not depend on the specificity of a given permeability factor.
局灶节段性肾小球硬化症是一种肾小球疾病,其复发率较高。虽然肾活检仍然是诊断局灶节段性肾小球硬化症复发的金标准,但非侵入性预后检测方法可以促进预防性治疗,并深入了解疾病的发病机制和异质性。Srivastava 等人描述了一种简单的基于细胞的检测方法来预测局灶节段性肾小球硬化症的复发。尽管该研究需要进一步优化和验证,但它的新颖之处在于它不依赖于特定通透性因子的特异性。